Skip to main content
GIFLF logo

Grifols, S.A. (GIFLF) Stock Price & Analysis

Grifols, S.A. (GIFLF) — price $12.72 (0.00%), as of the Nov 19, 2026 trading session; market cap $8.66B.

Educational signal · not a buy or sell recommendation · How to read this

$12.72 $0.00 (0.00%) Market Cap $8.66B

Grifols, S.A. · GIFLF

Grifols, S.A. is a global healthcare company specializing in the procurement, manufacture, and sale of therapeutic products, primarily hemoderivatives and plasma-derived medicines. It addresses chronic, rare, and life-threatening diseases through its Bioscience, Hospital, Diagnostic, and Bio Supplies divisions.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • OGN · Organon & Co. · 37 /100
  • BIIB · Biogen Inc. · 37 /100
  • GSK · GSK plc · 77 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$12.72
Change on the day0.00%
52-week range$10.13 – $13.90
Market capitalisation$8.66B—
Price / earnings (trailing)16.01
Shares traded on the day50

Price & events

Other perspectives

Council score for Grifols (GIFLF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Negative
ROE Neutral
Gross Margin Neutral

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Grifols (GIFLF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Grifols, S.A. (GIFLF) is the company analyzed here. It employs 25,258 people and is led by Jose Ignacio Abia Buenache. In Q3 FY2026 it reported revenue of €2.04B and net income of €162M. The market values it at $8.66B.

2 · Latest results

What do the latest results show for Grifols (GIFLF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of €2.04B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026€2.04B€162M€0.24 (diluted)
Q2 FY2026€1.87B€154M€0.23 (diluted)
Q1 FY2026€1.71B€73M€0.10 (diluted)
Q4 FY2025€1.98B€98M€0.14 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Grifols (GIFLF)?

Short answer · as of

The distress and quality screens read Altman Z 1.15 · Piotroski F 6. Trailing ratios: ROE 8.8% · ROA 2.4% · current ratio 2.33 · earnings yield 6.1% · free-cash-flow yield 10.6%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.15 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GIFLF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GIFLF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About GIFLF

These answers are editorial: 1 of these 8 answers is drawn from the GIFLF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is GIFLF a good stock to buy?

Stock Expert AI does not rate GIFLF buy, sell or hold. Grifols, S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the GIFLF stock price today?

The last price recorded for Grifols, S.A. (GIFLF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for GIFLF?

Grifols, S.A. faces several significant risks inherent to its specialized healthcare operations. A primary concern is the reliance on a stable and sufficient supply of plasma, which can be vulnerable to disruptions from global health events, donor availability, or regulatory changes in plasma collection.

What are the key factors to evaluate for GIFLF?

Evaluate GIFLF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This strategy could yield significant returns over the medium to long term, diversifying its revenue base. Not financial advice.

How frequently does GIFLF data refresh on this page?

GIFLF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven GIFLF's recent stock price performance?

Grifols, S.A. (GIFLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading position in plasma-derived medicines with a critical product portfolio for chronic and rare diseases. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider GIFLF overvalued or undervalued right now?

The trailing P/E of Grifols, S.A. (GIFLF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research GIFLF before investing?

Before investing in Grifols, S.A. (GIFLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.